EA201590349A1 - Режимы лечения - Google Patents
Режимы леченияInfo
- Publication number
- EA201590349A1 EA201590349A1 EA201590349A EA201590349A EA201590349A1 EA 201590349 A1 EA201590349 A1 EA 201590349A1 EA 201590349 A EA201590349 A EA 201590349A EA 201590349 A EA201590349 A EA 201590349A EA 201590349 A1 EA201590349 A1 EA 201590349A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment modes
- treatment
- hsdd
- disorders
- humans
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к соединениям, фармацевтическим композициям и способам для лечения всех нарушений половой функции у человека, включая гипоактивное нарушение полового влечения (HSDD) у субъекта.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261679999P | 2012-08-06 | 2012-08-06 | |
PCT/US2013/053843 WO2014025814A1 (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201590349A1 true EA201590349A1 (ru) | 2015-07-30 |
Family
ID=50068530
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590349A EA201590349A1 (ru) | 2012-08-06 | 2013-08-06 | Режимы лечения |
Country Status (15)
Country | Link |
---|---|
US (1) | US9517254B2 (ru) |
EP (1) | EP2879680A4 (ru) |
JP (2) | JP2015524474A (ru) |
KR (3) | KR20200128437A (ru) |
CN (2) | CN104884060A (ru) |
AU (2) | AU2013299725A1 (ru) |
BR (1) | BR112015002687A2 (ru) |
CA (1) | CA2881388A1 (ru) |
EA (1) | EA201590349A1 (ru) |
HK (2) | HK1211239A1 (ru) |
IL (1) | IL237150B (ru) |
MX (1) | MX2015001695A (ru) |
SG (3) | SG10201908587PA (ru) |
WO (1) | WO2014025814A1 (ru) |
ZA (1) | ZA201501562B (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2016001597A1 (es) * | 2016-06-17 | 2017-10-06 | S1 Biopharma Inc | Métodos de tratamiento de mujeres con trastornos de deseo sexual hipoactivo con tratamiento de combinación de bupropion y trazodona |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687771A (en) * | 1985-11-01 | 1987-08-18 | Bristol-Myers Company | Method for treatment of male impotence |
DE4321965A1 (de) * | 1993-07-01 | 1995-01-12 | Cytech Biomedical Inc | Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
JP2002322085A (ja) * | 2001-04-26 | 2002-11-08 | Kazuhito Tomizawa | 知的機能障害治療剤 |
UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
WO2004030524A2 (en) * | 2002-10-03 | 2004-04-15 | Pr Pharmaceuticals | Treatment of autism and similar disorders |
EP1605894A2 (en) * | 2003-03-05 | 2005-12-21 | PR Pharmaceuticals | Oxytocin controlled release formulations and methods of using same |
CN1946404A (zh) * | 2004-04-22 | 2007-04-11 | 贝林格尔·英格海姆国际有限公司 | 用于治疗性功能疾病ⅱ的新颖药物组合物 |
WO2005102342A1 (en) | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
US20060004076A1 (en) | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
EP1827450A4 (en) | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE |
JP2008538741A (ja) * | 2005-03-04 | 2008-11-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鬱病の治療用及び/又は予防用の医薬組成物 |
US9023793B2 (en) | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
AU2007313911A1 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica, N.V. | Treatment of Pervasive Developmental Disorders |
WO2008075162A2 (en) | 2006-12-15 | 2008-06-26 | Pfizer Limited | Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction |
WO2009016488A2 (en) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd. | Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods |
CN102159210A (zh) * | 2008-08-21 | 2011-08-17 | 吉瑞工厂 | 用于治疗cns障碍的方法 |
ES2615884T3 (es) * | 2009-01-20 | 2017-06-08 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Ácido sórbico y benzoico y sus derivados que aumentan la actividad de un neurofármaco |
AU2011252764B2 (en) * | 2010-05-14 | 2012-12-13 | Charlotte L. Keating | Neuropsychopharmacological treatment regimes for treating psychological disorders |
US20130085106A1 (en) * | 2010-05-19 | 2013-04-04 | The University Of North Carolina At Chapel Hill | Methods and formulations for oxytocin treatment of substance use, psychiatric and other disorders |
WO2012016229A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
PL2694065T3 (pl) * | 2011-04-04 | 2018-06-29 | S1 Biopharma, Inc. | Kompozycja do leczenia zaburzenia hipoaktywnego pożądania seksualnego |
-
2013
- 2013-08-06 WO PCT/US2013/053843 patent/WO2014025814A1/en active Application Filing
- 2013-08-06 SG SG10201908587P patent/SG10201908587PA/en unknown
- 2013-08-06 EP EP13827390.9A patent/EP2879680A4/en not_active Withdrawn
- 2013-08-06 SG SG10201709967YA patent/SG10201709967YA/en unknown
- 2013-08-06 US US14/420,112 patent/US9517254B2/en active Active
- 2013-08-06 CA CA2881388A patent/CA2881388A1/en not_active Abandoned
- 2013-08-06 KR KR1020207031031A patent/KR20200128437A/ko not_active Application Discontinuation
- 2013-08-06 JP JP2015526649A patent/JP2015524474A/ja not_active Ceased
- 2013-08-06 CN CN201380052215.1A patent/CN104884060A/zh active Pending
- 2013-08-06 SG SG11201500919PA patent/SG11201500919PA/en unknown
- 2013-08-06 BR BR112015002687A patent/BR112015002687A2/pt not_active IP Right Cessation
- 2013-08-06 CN CN201710010422.0A patent/CN106924259A/zh active Pending
- 2013-08-06 EA EA201590349A patent/EA201590349A1/ru unknown
- 2013-08-06 MX MX2015001695A patent/MX2015001695A/es unknown
- 2013-08-06 KR KR1020157006024A patent/KR20150063039A/ko not_active Application Discontinuation
- 2013-08-06 AU AU2013299725A patent/AU2013299725A1/en not_active Abandoned
- 2013-08-06 KR KR1020237027646A patent/KR20230136142A/ko not_active Application Discontinuation
-
2015
- 2015-02-08 IL IL237150A patent/IL237150B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01562A patent/ZA201501562B/en unknown
- 2015-12-10 HK HK15112183.5A patent/HK1211239A1/xx unknown
-
2016
- 2016-03-01 HK HK16102368.2A patent/HK1214505A1/zh unknown
-
2018
- 2018-05-30 JP JP2018103554A patent/JP2018150357A/ja active Pending
- 2018-07-11 AU AU2018205121A patent/AU2018205121A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2881388A1 (en) | 2014-02-13 |
WO2014025814A1 (en) | 2014-02-13 |
CN106924259A (zh) | 2017-07-07 |
EP2879680A4 (en) | 2016-06-01 |
CN104884060A (zh) | 2015-09-02 |
HK1214505A1 (zh) | 2016-07-29 |
BR112015002687A2 (pt) | 2019-12-17 |
SG10201908587PA (en) | 2019-10-30 |
EP2879680A1 (en) | 2015-06-10 |
ZA201501562B (en) | 2017-11-29 |
SG11201500919PA (en) | 2015-04-29 |
HK1211239A1 (en) | 2016-05-20 |
JP2018150357A (ja) | 2018-09-27 |
JP2015524474A (ja) | 2015-08-24 |
AU2013299725A1 (en) | 2015-03-26 |
SG10201709967YA (en) | 2018-01-30 |
US20150150946A1 (en) | 2015-06-04 |
IL237150A0 (en) | 2015-04-30 |
US9517254B2 (en) | 2016-12-13 |
MX2015001695A (es) | 2015-09-28 |
KR20150063039A (ko) | 2015-06-08 |
AU2018205121A1 (en) | 2018-07-26 |
KR20230136142A (ko) | 2023-09-26 |
KR20200128437A (ko) | 2020-11-12 |
IL237150B (en) | 2018-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201491412A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
TN2014000319A1 (en) | Imidazopyrrolidinone compounds | |
EA201591524A1 (ru) | Производные 2-аминопиримидина для лечения вирусных инфекций | |
EA201691940A1 (ru) | Новые соединения | |
EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201491330A1 (ru) | Терапевтически активные соединения и способы их использования | |
EA201691259A1 (ru) | РЕГУЛЯТОРЫ Nrf2 | |
EA201591616A1 (ru) | Трифторметил-замещенные аннелированные пиримидины и их применение | |
EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201491579A1 (ru) | Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA202190619A1 (ru) | Противовирусные соединения | |
EA201790963A1 (ru) | Противовирусные соединения | |
EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
EA201591648A1 (ru) | Бензимидазол-2-ил-пиримидиновые модуляторы рецептора гистамина h4 | |
EA201400165A1 (ru) | Частицы на основе полиакрилата, которые содержат активное соединение | |
EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний |